

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS ✓
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 7/48</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/13661</b> <b>(43) International Publication Date:</b> 16 March 2000 (16.03.00)
<b>(21) International Application Number:</b> PCT/US99/20854 <b>(22) International Filing Date:</b> 10 September 1999 (10.09.99) <b>(30) Priority Data:</b> 60/099,698 10 September 1998 (10.09.98) US <b>(71) Applicant (for all designated States except US):</b> AVON PRODUCTS, INC. [US/US]; 1251 Avenue of the Americas, New York, NY 10020-1196 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> DURAISWAMI, Chaya [IN/US]; 146 Sandpiper Key, Seacaucus, NJ 07094 (US). SIMPSON, Susan, E. [CA/US]; 349 Wyckoff Avenue, Wyckoff, NJ 07481 (US). GARRISON, Mark, S. [US/US]; 10 Chestnut Street, Suffern, NY 10901 (US). MARTIN, Dennis, M. [US/US]; 8 Tenney Lane, Cornwall, NY 12518 (US). BLOOM, Roberta, C. [US/US]; 15 Oak Hill Lane, Shelton, CT 06484 (US). <b>(74) Agent:</b> RUGGIERO, Charles, N., J.; Ohlandt, Greeley, Ruggiero & Perle, LLP, One Landmark Square, Stamford, CT 06901-2682 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SF), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD AND COMPOSITIONS FOR REDUCING DERMATOLOGICAL AGING AND FOR REDUCING BRUISING <b>(57) Abstract</b>  Methods to reduce susceptibility to, severity or duration of, bruising of skin and topical compositions for practicing such methods. The topical compositions comprise an isoflavonoid and a vehicle. The invention also includes a synergistic topical composition that includes, in addition to the isoflavonoid and vehicle, secondary components selected from specific classes of compounds.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHOD AND COMPOSITIONS FOR REDUCING  
DERMATOLOGICAL AGING AND FOR REDUCING BRUISING**

**1. Field of the Invention**

5           The present invention relates to topical compositions and methods  
of using same for improving overall dermatological health. The present  
invention also relates to compositions for reducing susceptibility to bruising  
and for decreasing the healing time for bruises that occur and to methods  
for using these compositions. The present invention further relates to  
10   topical compositions to alleviate dermatological symptoms associated with  
hormonal aging and methods for using same.

**2. Description of the Related Art**

          Aging of the skin results from the synergistic effects of intrinsic aging  
15   (due to age and genetic factors), photoaging (due to exposure to ultraviolet  
radiation), and, for women, hormonal aging (due to estrogen deficiency in  
peri-menopausal and menopausal women.) Such dermatological aging  
manifests as skin wrinkles, pigmentation/age spots, sallowness, sagging  
skin, thinning of skin, a decrease in skin's elasticity and resilience. One  
20   cause of the foregoing manifestations of dermatological aging is a net loss  
of collagen fibers in skin. This net loss of skin collagen fibers results in  
thinning of the dermis. Because the dermis acts to "cushion" the force of  
impact, this decrease in the thickness of the dermis can result in increased  
bruising.

25           In addition, some women also experience an increase in acne  
because of these hormonal changes.

          A need exists for a composition and method that will retard or  
30   reverse the negative dermatological effects associated with hormonal  
aging. A further need exists for a composition and method that will  
accomplish the foregoing with minimal adverse effects.

PCT publication WO 98/21946 to Wurtman et al. (the disclosure of which is incorporated herein by reference) provides dietary supplements that include phytoestrogen compounds, and either (a) remedial carbohydrates, (b) choline compounds or (c) both.

5

PCT publication WO 98/56373 to Gorbach (the disclosure of which is incorporated by reference herein) provides topical compositions that utilize purified isoflavonoids, such as genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol. Gorbach also provides topical compositions having between 1 and 40mg of purified isoflavones per gram of base (i.e. 0.1 wt% to 4 wt%) for treating and preventing wrinkles. Gorbach defines "purified isoflavonoid" as an isoflavonoid in a more concentrated form than occurs in plants.

10

U.S. Patent No. 5,166,132 to Gordon provides topical compositions having an improved enzyme-modified casein solution that are useful for healing and relieving bruising.

#### BRIEF SUMMARY OF THE INVENTION

15

It is an object of the present invention to provide topical compositions and methods to reduce dermatological aging.

20

It is another object of the present invention to provide topical compositions and methods to reduce susceptibility to bruising.

25

It is further an object of the present invention to provide topical compositions and methods to reduce the severity of and healing period for bruises that do manifest.

## DETAILED DESCRIPTION OF THE INVENTION

A "topical composition" as used herein refers to a composition intended to be directly applied or spread on the surface of skin. An "effective amount" means an amount of a compound or a composition sufficient to induce a positive change in the skin condition. A "physiologically acceptable vehicle" or a "suitable topical vehicle" refers to a drug, cosmetic, medicament or inert ingredient that is suitable for use in direct contact with human tissues without undue toxicity. All percentages refer to weight percent, based on the total weight of the topical composition.

The first principal component of the present compositions is a phytoextract. The phytoextract is preferably a phytoestrogen and, more preferably, either a (1) isoflavone, (2) steroidal, (3) sterol, (4) coumestan, (5) lignan, or (6) any mixture thereof.

The term "phytoextract" as used herein encompasses all such compounds that occur naturally in plants regardless of whether the actual compound used in the present invention is extracted from plant sources or manmade. As stated above, it is preferred that the phytoextract is a phytoestrogen. Preferably, the phytoextract is derived from plant sources. In the more preferred embodiment, the phytoextract is a phytoestrogen that is naturally derived. Alternatively, the phytoextract may be synthetically derived. "Phytoestrogen" as used herein refers to compounds that are either (a) known to exhibit an estrogen-type effect or (b) specifically set forth herein as a phytoestrogen.

Exemplary phytoextracts and their sources are set forth below in Table 1.

TABLE 1

Phytoextract Active	Source
Segetalins B, C, and D	<i>Vaccaria segetalis</i>
Isoflavone 6-Prenylisocaviunin	<i>Sopubia delphinifolia</i>
3'-Prenyl-4'methoxy-isoflavone-7-O- $\beta$ -D-(2'O-p-coumaroyl glucopyranoside)	
Kaempferol, $\beta$ -Sitosterol,	Fennel ( <i>Foeniculum vulgare</i> )
Cimifugin or Macroton, Cimigenol or Cimifugol, Cimigoside or C.migenol Xyloside, Formononetin Isoferulic acid, Cimifugoside	Black Cohosh ( <i>Cimifuga racemosa</i> )
Daidzein, Genistein, Equol	Soy ( <i>Glycine Max</i> )
Liqcoumarin, 6-Acetyl-5-hydroxy-4-methylcoumarin, Formononetin, Glabridin, Hispaglabridin-A, Hispaglabridin-B, Isoliquiritigenin	Licorice ( <i>Glycyrrhiza glabra</i> )
Genistin, Biochanin A, Coumesterol, Formononetin	Alfalfa ( <i>Medicago sativa</i> )
$\beta$ -Sitosterol, Biochanin-A	Bourbon
$\beta$ -sitosterol, Genistein, Daidzein	Beer
$\beta$ -Sitosterol,	Saw Palmetto
Naringenin	Eucalyptus, Citrus Fruits, e.g. Oranges, Lemons
Humulone, Xanthohumol, Lactic acid	Hops
Coumestans, 25-Dehydro-sitosterol, 23-Dehydro- $\beta$ -sitosterol, Phytosterols	Sunflower
Estradiol, Estrone Phytosterol $\beta$ -Sitosterol	Pomegranate
Phytosterol, Coumesterol, Indole-3-Carbinol, Quercitin	Brussel sprouts
Diosgenin, DHEA	Yam ( <i>Dioscorea Species</i> )
Biochanin A, Formononetin, Genistin, Coumesterol	Red Clover ( <i>Trifolium pratense</i> )
Matairesinol Enterodiol, Enterolactone	Palm
Brassicasterol, Campesterol, $\beta$ -Sitosterol, Stigmasterol	Canola
Zearalenone sulfate	<i>Fusarium species</i>
Biochanin A	Legumes



Furanoid Lignans	Chaparral ( <i>Larrea tridentata</i> )
Matairesinol	Rye

The more preferred phytoextracts are phytoestrogens, such as daidzein, daidzin, acetyl daidzin, malonyl daidzin, glycitin, acetyl glycitin, malonyl glycitin, glycitein, genistin, acetyl genistin, malonyl genistin,  
5 genistein, equol, and any mixture thereof. The most preferred phytoextracts are daidzein, glycitein, genistein, equol and any mixture thereof. When the phytoextract is daidzein, glycitein, genistein, equol, and any mixture thereof, the topical composition preferably comprises from about 0.01 wt% to about 0.1 wt% phytoextract, more preferably from about  
10 0.015 wt% to about 0.08 wt% phytoextract, and most preferably from about 0.02 wt% to 0.072 wt% phytoextract.

Examples of preferred plant sources include soy, soy bean, red clover, pomegranate, saw palmetto, canola, and any mixture thereof.  
15

In addition to the phytoextract component, the present invention preferably includes a secondary component. The secondary component is selected from one or more of the following twelve groups.

- 20 1. An estrogen synthetase stimulating compound: Examples of such a compound include caffeine and/or derivatives thereof, and any mixture thereof. Caffeine is the more preferred of such compounds.
2. A compound capable of inhibiting 5 alpha-reductase activity: Examples  
25 of such a compound include linolenic acid, linoleic acid, finasteride, and any mixture thereof.
3. An exfoliation promoting compound: Suitable examples include alpha hydroxy acids; beta hydroxy acids; oxa acids as disclosed in U.S. Patent  
30 No. 5,847,003 (the disclosure of which is incorporated by reference

herein); oxa diacids as disclosed in U.S. Patent No. 5,834,513 (the disclosure of which is incorporated by reference herein); mechanical exfoliation compounds, such as bamboo exfoliant extract; salicylic acid; benzoyl peroxide; alpha-keto acids, such as pyruvic acid, 2-oxopropanoic acid, 2-oxobutanoic acid, and 2-oxopentanoic acid; and any mixture thereof.

- The preferred exfoliation promoting compounds are lactic acid, glycolic acid, 3,6,9-trioxaundecanedioic acid, and any mixture thereof.
- 10 When present invention includes an exfoliation promoting compound, the composition comprises about 1 wt% to 20 wt%, preferably 1 wt% to about 15 wt%, more preferably about 4 wt% to about 10 wt% acid, and most preferably about 4 wt% of the exfoliation promoting compound.
- 15 4. An ultraviolet (UV) light protecting/sunscreen agent: Examples include organic and inorganic sunscreens, such as titanium dioxide, zinc oxide, methyl benzylidene camphor and/or its derivatives, octocrylene, anthranilates, benzophenones, butylmethoxydibenzoylmethane (avobenzone), naphtholsulphonates, benzoic acid derivatives, salicylates,
- 20 cinnamic acid derivatives, and mixtures thereof. Of these, butylmethoxydibenzoylmethane (PARSOL 1789), octocrylene, octylsalicylate, octylmethoxycinnamate and oxybenzone, and mixtures thereof are preferred. Butylmethoxydibenzoylmethane or avobenzone (PARSOL 1789), oxybenzone and octylmethoxycinnamate, and mixtures
- 25 thereof are most preferred. In addition, U.S. Patent No. 5,824,702, to Wei (the disclosure of which is incorporated by reference herein) provides that genistein exhibits protective activity against ultraviolet induced skin photodamage and cancer. Co-formulation with an ultraviolet light protecting/sunscreen agent is particularly desirable when the present
- 30 invention is prepared for consumers who engage in outdoor activities.

5. Retinoids: Examples of suitable retinoids include retinol, retinoic acid, retinyl palmitate, retinyl propionate, retinyl acetate, isotretinoin as well as synthetic retinoid mimics, and derivatives of the foregoing.

5 6. Hirsutism inhibiting agents: Examples of such agents include  $\gamma$ -linolenic acid, linoleic acid, and derivatives thereof.

7. Barrier function enhancing agents: Examples include ceramides, essential fatty acids and their esters, especially glycerides,  $\alpha$ -hydroxy fatty acids and their esters derived with alkanols through carboxylic hydroxyl or with other fatty acids at the omega-hydroxyl, the latter type being most preferred, with phospholipids, cholesterol and its esters, such as cholesteryl hemisuccinate and cholesteryl phosphate of which cholesterol phosphate and essential fatty acids are most preferred, cholestanol and its derivatives. The barrier function enhancing agent can be added to a topical composition either as singular molecular entities or as a complex mixture of lipids derived from either synthetic, animal or plant sources.

8. Collagen enhancing agents: These agents prevent skin sagging by promoting a net increase in collagen, either by reducing collagen breakdown or by promoting collagen formation. Examples of such inhibitors include *Clara* extract (*Sophora augustifolia*), ascorbyl-phosphoryl-cholesterol, ascorbic acid, ascorbic acid derivatives, and any mixtures thereof.

25

9. Elastase inhibitors: Examples of these inhibitors include Honeysuckle extract (*Lonicera caprifolium*). These inhibitors act to prevent sagging of the skin.

10. Skin lightening agents: Examples include kojic acid, hydroquinone, licorice derivatives, ascorbic acid/ascorbic acid derivatives (e.g. magnesium ascorbyl phosphate), arbutin, bearberry (*Arctostaphylos uva*

ursi), *Glycyrrhiza glabra* and its derivatives, *Chlorella vulgaris* extract, and—  
any mixture thereof.

11. Antioxidants: Examples include compounds having phenolic  
5 hydroxy functions, such as ascorbic acid, ascorbic acid derivatives, gallic  
acid derivatives (e.g. propyl gallate); ferulic acid derivatives (e.g. ethyl  
ferulate, sodium ferulate); nitrones; N-tertbutyl-nitron; 1-(4-pyridyl-1-oxide)-  
N-tertbutyl-nitron; curcumin, tetrahydrocurcumin; 6-hydroxy-  
2,5,7,tetramethylchroman-2-carboxylic acid; uric acid; reductic acid; tannic  
10 acid; rosmarinic acid; tocopherol and its derivatives; catechins; and any  
mixtures thereof. Other suitable antioxidants are those that have one or  
more thiol functions (-SH), in either reduced or non-reduced form, such as  
glutathione, lipoic acid, thioglycolic acid, and other sulfhydryl compounds.  
The antioxidant may be inorganic, such as sulfites, bisulfites, metabisulfite,  
15 or other inorganic salts and acids containing sulfur.

12. Skin cooling compounds: Examples include menthol, menthyl glycerol,  
asymmetrical carbonates, thiocarbonates and urethanes, N-substituted  
carboxamides, ureas or phosphine oxides, menthyl lactate, menthone  
20 glycerine acetal, and any mixtures thereof. Since many women experience  
“hot flashes/flushes” during perimenopause, coformulation with skin  
cooling compounds is particularly desirable when providing topical  
compositions of the present invention for such women.

25 The secondary component enhances the dermatological benefits  
achieved by the phytoextract. It is more preferred that the compositions of  
the present invention include at least two secondary components with each  
secondary component being selected from a different group. Table 2,  
below, sets forth examples of such preferred combinations.

30

**TABLE 2**

Examples of combinations of phytoestrogen with secondary component.

Formula Number	1	2	3	4	5	6	7	8	9	10	11	12
Phytoestrogen	X	X	X	X	X	X	X	X	X	X	X	X
Glycolic Acid	X	X	X					X				X
Lactic Acid				X					X			
Oxa Acid						X						X
Retinol				X	X					X	X	X
Ascorbyl-phosphoryl-cholesterol							X	X				X
Ascorbic Acid	X								X	X		X
Octylmethoxycinnamate	X	X		X	X	X	X	X	X	X	X	X
Oxybenzone	X	X		X	X	X	X	X	X	X	X	X
Avobenzone	X	X		X	X	X	X	X	X			X
Licorice root		X	X									X
Tetrahydro-curcumin			X									X
Nitric Oxide Synthase Inhibitor											X	X

- The compositions of the present invention can include other
- 5 cosmetic and pharmaceutical actives and excipients. Such suitable cosmetic and pharmaceutical agents include, but are not limited to, antifungals, vitamins, anti-inflammatory agents, antimicrobials, analgesics, nitric oxide synthase inhibitors, insect repellents, self-tanning agents, surfactants, moisturizers, stabilizers, preservatives, antiseptics, thickeners,
- 10 lubricants, humectants, chelating agents, skin penetration enhancers, emollients, fragrances and colorants.

Examples of suitable thickening agents include xanthan gum, hydroxypropyl cellulose, hydroxyethyl cellulose, carbomer, gum acacia, Seppigel 305 (available from Seppic Co., France), and magnesium aluminum silicate.

5

The topical compositions of the present invention can include, and their utility can be enhanced by, humectants, such as urea, pyrrolidone carboxylic acid, amino acids, sodium hyaluronate, certain polyols and other compounds with hygroscopic properties.

10

Topical compositions of the present invention can also include one or more of the following:

(i) vitamins, such as any B vitamin; 1,25-dihydroxy vitamin D3; vitamin K; tocopherol and its derivatives; tocotrienols and their derivatives; nicotinic acid and its esters; pantothenic acid and its esters; panthenol; folic acid and its derivatives; phytic acid; ascorbic acid and its derivatives; vitamin A and its derivatives; and any mixtures thereof;

20 (ii) antifungals, such as tolnaftate and ketoconazole;

(iii) self-tanning agents, such as dihydroxyacetone and lawsone;

(iv) anti-microbial agents, such as erythromycin and tetracycline;

25

(v) topical analgesics, such as lidocaine, benzocaine, butacaine, tetracaine, clove oil and eugenol;

(vi) anti-inflammatory agents may be included in topical compositions of the present invention. These anti-inflammatory agents are used at concentrations from about 0.025 wt% to about 10 wt%, preferably, about 0.5 wt% to about 1 wt%, with the concentration of the anti-

inflammatory adjusted upward or downward depending upon the potency —  
of the utilized agents. Examples include hydrocortisone, prednisone,  
prednisolone, aspirin, aspirin derivatives, aloe vera, willow bark,  
chamomile, and mixtures thereof;

5

(vii) nitric oxide synthase inhibitors that reduce skin redness,  
vasodilation and inflammatory reactions, especially in response to  
electromagnetic and ionizing radiation or to the action of chemically or  
biochemically aggressive compounds can be included in the present  
10 invention. The nitric oxide synthase inhibitors are more preferably selected  
from the group including guanidine derivatives, especially  
monoaminoguanidine and methylguanidine, L-arginine derivatives,  
especially NG-nitro-L-arginine and its esters, NG-monomethyl-L-arginine,  
2-iminopiperidines, asymmetric dimethyl arginine (ADMA), boronic acid  
15 analog of L-arginine (Boroarg-OH•2HCl), and other 2-  
iminoazaheterocycles;

(viii) insect repellents, such as aliphatic, cyclic or aromatic amides,  
citronella oil, terpineol, cineole, neem oil, terephthalic acid and its esters,  
20 ethyl butylacetylaminopropionate and N,N-diethyl-m-toluamide (DEET)  
may be included in the present invention. Coformulation with insect  
repellents can be particularly desirable when the present invention is used  
to prevent bruising. For those who engage in vigorous outdoor activities,  
such as hiking and other sports, having an insect repellent incorporated  
25 into the present invention provides a convenient two-in-one preventative  
measure.

The vehicle can comprise most conventional emollients including  
mineral oil, petrolatum, paraffin, ceresin, ozokerite, microcrystalline wax,  
30 perhydrosqualene dimethyl polysiloxanes, methylphenyl polysiloxanes,  
silicone-glycol copolymers, triglyceride esters, acetylated monoglycerides,  
ethoxylated glycerides, alkyl esters of fatty acids, fatty acids and alcohols,

lanolin, lanolin derivatives, polyhydric alcohol esters, sterols, beeswax derivatives, polyhydric alcohols and polyethers, and amides of fatty acids.

5       The emulsifiers can be cationic, anionic, nonionic, amphoteric, or a combination thereof. Nonionic emulsifiers are preferred. Exemplary nonionic emulsifiers are commercially available sorbitans, alkoxyated fatty alcohols and alkyl polyglycosides. Anionic emulsifiers may include soaps, alkyl sulfates, monoalkyl and dialkyl phosphates, alkyl sulphonates and acyl isothionates.

10

      The preservatives suitable for use with the present compositions include alkanols, especially ethanol and benzyl alcohol, parabens, sorbates, benzoic acid/benzoates, urea derivatives, and isothiazolinones.

15

      The general activity and mildness to skin of the present topical compositions can also be enhanced by neutralization to pH about 3.5 to about 7.0, most preferably from pH about 3.7 to about 5.6, with one or more of ammonium hydroxide, potassium hydroxide, sodium hydroxide, arginine or other amino acids, and/or triethanolamine.

20

      The utility of the present topical compositions can also be enhanced by certain chelating agents incorporated into the composition at levels from about 0.01% to about 25% by weight, more preferably from about 0.5% to 10%, and most preferably from about 1% to about 5%. Suitable examples  
25   of chelating agents include those that have a high affinity for zinc, calcium, magnesium, iron and/or copper ions, such as ethylene-diamine-tetra-acetic acid.

      The topical compositions of the present invention can be further  
30   formulated according to procedures known in the art to provide cosmetic compositions such as emulsions, gels, creams, lotions, ointments, pastes, sticks, cakes, pencils, essences and serums as well as other topical



cosmetic vehicles. It is also contemplated that topical compositions of the present invention can be incorporated into delivery systems such as liposomes and topical patches, tapes, and sprays.

5           The topical compositions of the present invention are useful to improve the aesthetic appearance of skin by any one of the following methods:

1. Reducing dermatological aging, particularly dermatological aging due to hormonal aging;
- 10       2. Decreasing skin fragility;
3. Preventing and reversing loss of collagen;
4. Preventing skin atrophy;
5. Promoting/accelerating cell turnover;
6. Providing cushion for blood vessels;
- 15       7. Improving skin texture;
8. Decreasing fine lines and wrinkles;
9. Improving skin tone;
10. Enhancing skin thickness;
11. Decreasing pore size;
- 20       12. Minimizing skin discoloration;
13. Restoring skin luster;
14. Minimizing signs of fatigue;
15. Reducing acne;
16. Decreasing susceptibility to bruising; and
- 25       17. Decreasing severity of bruising;
18. Decreasing time required for healing of bruises.

The present invention also includes methods by which these compounds can be used to address the aforementioned skin conditions.

30       Such methods include topically applying an effective amount of the composition of the present invention to areas of the skin, typically once or twice daily. When the present invention is used to improve the overall

aesthetic appearance of skin, the preferred areas of application include the face and neck areas. When the present invention is used to reduce susceptibility, severity and healing time of bruises, preferred areas of application include hands, arms (particularly, forearms), legs (particularly, lower leg areas), hips and any other areas subject to impact.

### EXAMPLE 1

Thirty-seven women participated in a twelve week clinical study to evaluate the efficacy of a topical composition, Sample A, in increasing the thickness of the skin. The women treated one forearm with a test product for twelve weeks. The arm to be treated (right or left) was assigned randomly as the test area. Treatment was once every morning and sample A was applied to the test area.

#### SAMPLE A

15	<u>Ingredients</u>	<u>wt%</u>
	lactic acid (85%)	4.71
	soy extract (0.08%)	25.00
	vehicle	qs

The skin was then assessed visually at four weeks and at eight weeks. Visual improvements of the treated arm were very evident. At four weeks, the skin looked and felt smoother. The skin also appeared brighter. At eight weeks, pigment discolorations looked lighter, and the skin had a much better overall appearance. If the treated skin was laterally compressed, the treated skin was far more resistant to compression. Untreated skin compressed easily, resulting in visible crinkling.

It is believed that the resistance to compression exhibited by the treated skin was the result of the epidermis and dermis becoming "plumper" or thicker. The resulting increase in the thickness is believed to be result of activity of the lactic acid, the soy extract, or the combination of the two materials.

## EXAMPLE 2

Since thicker skin provides more "cushion," which might result in less of a bruise from an impact or a pinch, the following twelve week study  
5 was conducted to determine the efficacy of the present invention to reduce the susceptibility of the skin to bruising.

The test utilized Sample A set forth above. Fifteen of the thirty-seven women who participated in the test discussed in Example 1, above,  
10 agreed to have their arms bruised at the twelve-week time point. All of these women were post-menopausal.

The volar forearm was bruised using a pinch method. The skin was given a calibrated pinch using Lange Skinfold Calipers. Both treated and  
15 untreated volar forearms were pinched approximately two inches from the elbow flex region.

The women returned to the laboratory at one day, four days, and seven days after bruising. Minolta chromameter L-a-b measurements (an  
20 objective measurement of skin color) were taken prior to bruising and on the post-bruising follow-up days. Each woman also completed a self-assessment questionnaire on the evaluation days.

Four days post-bruising was selected as the best day for bruise  
25 assessments. Not all bruises appeared the first day after bruising, but all bruises appeared within four days of trauma. Furthermore, of those bruises that appeared early (one day post-trauma) some had completely resolved seven days later. Therefore, day four post-bruising was selected as the best time point to assess bruises.

30

### L-a-b Color Measurements of Bruises

Chromameter measurements done in the L-a-b mode assessed

three color components of the bruise color. The "L" value is an assessment of light/dark. The "a" value is an assessment of red/green. The "b" value is an assessment of yellow/blue. The following are the average change from baseline (normal skin color) values obtained for "L", "a" and "b".

5

Change from Baseline Values - 4 Days Post-Bruising

	<u>Treated</u>	<u>Untreated</u>
L(Light)	-1.1	-2.9
a (red)	0.26	2.02
b (yellow)	1.7	2.8

10

The higher the "L" value the lighter the skin. Therefore, the untreated bruised skin was darker (or more bruised) than the treated bruised skin. The "a" value increases with greater redness. Untreated bruises were redder than treated bruises. The yellow component of the bruise, the "b" value, is more yellow with a greater number. The "b" value can also be a blue measurement, however, most of the values obtained were in the yellow range (positive) of the scale. The average "b" value for untreated skin was greater for untreated skin than treated skin.

20

The majority of the panelists had less bruising on the treated arm. The following chart shows the number of panelists with better "L" (lighter), "a" (less red) or "b" (less yellow) values for the treated or untreated arm:

25

Number of Panelist with Better Values - Day 4 Post-Bruising

	<u>Treated</u>	<u>Untreated</u>
Lighter(L)	11	4
Less Red (a)	10	5
Less Yellow (b)	11	4

30

Tables with individual data for "L", (Table 3), "a" (Table 4), and "b" (Table 5) are set forth below.

**TABLE 3**

Change from Baseline in "L" Value (Bruise Darkness) - Day 4 Post-Bruising

Subject #	Treated Arm	Untreated Arm	Which Better
1	-6.9	-5.5	U
2	-1.6	-3.9	T
3	0.2	-9.4	T
4	-1.3	1.5	U
5	-0.4	-1.3	T
6	-3.5	-9.4	T
7	2.2	3.4	U
8	0.7	-2.6	T
9	-2.5	-3.3	T
10	0.4	-4.1	T
11	-3.9	-3.7	U
12	0.2	-0.2	T
13	0.8	-2.0	T
14	0.7	-1.0	T
15	-0.7	-3.3	T
AVERAGE	-1.1	-2.9	

5 Note: The higher the "L" value, the lighter the skin.

**TABLE 4**

Change from Baseline in "a" Value 4 Days Post Bruising

Subject #	Treated Arm	Untreated Arm	Which Better
1	3.5	3.3	U
2	1.0	3.3	T
3	-0.2	5.9	T
4	-0.3	-0.9	U
5	1.0	0.3	U
6	-1.3	5.2	T
7	-2.0	-2.8	U
8	0.3	2.7	T
9	1.0	0.9	U
10	-0.2	2.4	T
11	1.5	4.6	T
12	-0.7	0.2	T
13	0.2	2.2	T
14	-0.8	1.3	T
15	0.9	1.7	T
AVERAGE	0.26	2.02	

Note: A higher "a" value indicates skin is redder.

**TABLE 5**  
Change from Baseline in "b" Value 4 Days Post Bruising

Subject #	Treated Arm	Untreated Arm	Which Better
1	5.9	6.5	T
2	1.9	3.9	T
3	0.4	5.2	T
4	2.6	2.9	T
5	0.1	0.0	U
6	5.5	3.9	U
7	-0.3	-1.8	U
8	0.4	3.6	T
9	0.4	2.5	T
10	2.4	5.6	T
11	6.8	0.6	U
12	1.0	2.0	T
13	-0.8	1.1	T
14	-1.3	2.7	T
15	0.5	3.1	T
AVERAGE	1.7	2.8	

Note: Higher "b" value indicates skin is more yellow.

5

The data clearly suggest that daily use of a product, such as Sample A, can help reduce the susceptibility to bruising. Bruising may still occur, but bruises may be less severe.

10

Various modifications and alterations to the present invention may be appreciated based on a review of this application. These changes and additions are intended to be within the scope and the spirit of the present invention as defined by the following claims.

## CLAIMS

What is claimed is:

1. A method for reducing susceptibility to, severity or duration of  
5 bruising comprising applying a topical composition comprising a  
phytoextract and a vehicle.
2. The method of claim 1, wherein the phytoextract is a phytoestrogen.
- 10 3. The method of claim 2, wherein the phytoestrogen is selected from  
the group consisting of: isoflavones, steroidal, sterols, coumestans,  
lignans, and any mixture thereof.
4. The method of claim 1, wherein the phytoextract is selected from  
15 the group consisting of: daidzein, daidzin, acetyl daidzin, malonyl daidzin,  
glycitin, acetyl glycitin, malonyl glycitin, glycitein, genistin, acetyl genistin,  
malonyl genistin, genistein, equol, and any mixture thereof.
5. The method of claim 1, wherein the phytoextract is from about  
20 0.01 wt% to about 0.1 wt% of the topical composition.
6. The method of claim 1, wherein the topical composition further  
comprises a secondary component selected from the group consisting of:
  - (i) an estrogen synthetase stimulating compound;
  - 25 (ii) a 5 alpha-reductase activity inhibiting compound;
  - (iii) an exfoliation-promoting compound;
  - (iv) an ultraviolet (UV) light protecting/sunscreen agent;
  - (v) a retinoid;
  - (vi) a hirsutism inhibiting agent;
  - 30 (vii) a barrier function enhancing agent;
  - (viii) a collagen enhancing agent;
  - (ix) an elastase inhibitor;

- (x) a skin lightening agent
- (xi) an antioxidant;
- (xii) a skin cooling agent; and
- (xiii) any mixtures thereof.

5

7. The method of claim of claim 6, wherein the secondary component is the exfoliation-promoting compound selected from the group consisting of alpha-hydroxy acids,  $\beta$ -hydroxy acids, keto acids, oxa acids, oxa diacids, derivatives thereof, and any mixture thereof.

10

8. The method of claim 6, wherein the exfoliation-promoting compound is selected from the group consisting of: lactic acid; glycolic acid; 3,6,9-trioxaundecanedioic acid, and any mixtures thereof.

15 9. The method of claim 6, wherein the topical composition comprises two or more secondary components and each of said secondary components is selected from a different group of said secondary components.

20 10. The method of claim 6, wherein the topical composition further comprises a tertiary component selected from the group consisting of: antifungals, vitamins, anti-inflammatory agents, antimicrobials, analgesics, nitric oxide synthase inhibitors, insect repellents, self-tanning agents, surfactants, moisturizers, stabilizers, preservatives, antiseptics, thickeners,  
25 lubricants, humectants, chelating agents, skin penetration enhancers, emollients, fragrances, colorants, and any mixture thereof.

11. The method of claim 1, wherein the method includes applying topical composition twice daily.

30



12. The method of claim 1, wherein the vehicle is selected from the group consisting of: solid, solution, essence, serum, pencil, spray, lotion, emulsion, cream, micro-emulsion, gel, ointment, patch, tape, and powder.
- 5 13. A method for reducing susceptibility to, severity or duration of bruising in perimenopausal or menopausal women comprising applying a topical composition comprising a phytoestrogen and a vehicle.
14. A method of improving the aesthetic appearance of skin comprising  
10 topically applying a composition comprising a phytoestrogen and a vehicle.
15. The method of claim 14, wherein the phytoestrogen comprises from about 0.01wt% to about 0.08 wt% of the topical composition.
- 15 16. The method of claim 15, wherein the phytoestrogen is selected from the group consisting of: daidzein, daidzin, acetyl daidzin, malonyl daidzin, glycitin, acetyl glycitin, malonyl glycitin, glycitein, genistin, acetyl genistin, malonyl genistin, genistein, equol, and any mixture thereof.
- 20 17. The method of claim 14, wherein the topical composition further comprises a secondary ingredient selected from the group consisting of:
- (i) an estrogen synthetase stimulating compound;
  - (ii) a 5 alpha-reductase activity inhibiting compound;
  - (iii) an exfoliation-promoting compound;

25 (iv) an ultraviolet (UV) light protecting/sunscreen agent;

  - (v) a retinoid;
  - (vi) a hirsutism inhibiting agent;
  - (vii) a barrier function enhancing agent;
  - (viii) a collagen enhancing agent;

30 (ix) an elastase inhibitor;

  - (x) a skin lightening agent;
  - (xi) an antioxidant;

- (xii) a skin cooling agent; and
- (xiii) any mixtures thereof.

18. The method of claim 17, wherein the improvement in aesthetic  
5 appearance includes at least one of the following:

- a. Decreasing skin fragility;
- b. Preventing and reversing loss of collagen;
- c. Preventing skin atrophy;
- d. Improving skin firmness/plumpness;
- 10 e. Improving skin tone;
- f. Enhancing skin thickness; and
- g. Decreasing pore size.

19. The method of claim 14, wherein the improvement in aesthetic  
15 appearance includes at least one of the following:

- a. Reducing dermatological aging, particularly dermatological  
aging due to hormonal aging;
- b. Decreasing skin fragility;
- c. Preventing and reversing loss of collagen;
- 20 d. Preventing skin atrophy;
- e. Promoting/accelerating cell turnover
- f. Improving skin firmness/plumpness;
- g. Improving skin texture;
- h. Decreasing fine lines and wrinkles;
- 25 i. Improving skin tone;
- j. Enhancing skin thickness;
- k. Decreasing pore size.
- l. Minimizing skin discoloration;
- m. Restoring skin luster;
- 30 n. Minimizing signs of fatigue; and
- o. Reducing acne.

20. The method of claim 19, wherein the improvement in aesthetic appearance includes at least one of the following:
- a. Decreasing skin fragility;
  - b. Preventing skin atrophy;
  - 5 c. Improving skin firmness/plumpness; and
  - d. Enhancing skin thickness.
21. The method of claim 19, wherein the vehicle is selected from the group consisting of a solid, solution, essence, serum, pencil, spray, lotion, emulsion, cream, micro-emulsion, gel, ointment, patch, tape, and powder.
22. A topical composition comprising:
- a. a phytoestrogen;
  - b. a vehicle; and
  - 15 c. at least one secondary component selected from the group consisting of:
- (i) an estrogen synthetase stimulating compound;
  - (ii) a 5 alpha-reductase activity inhibiting compound;
  - (iii) an exfoliation-promoting compound;
  - 20 (iv) an ultraviolet (UV) light protecting/sunscreen agent;
  - (v) a retinoid;
  - (vi) a hirsutism inhibiting agent;
  - (vii) a barrier function enhancing agent;
  - (viii) a collagen enhancing agent;
  - 25 (ix) an elastase inhibitor;
  - (x) a skin lightening agent
  - (xi) an antioxidant;
  - (xii) a skin cooling agent; and
  - (xiii) any mixtures thereof.

30

23. The topical composition of claim 22, wherein the at least one secondary component is selected from the group consisting of:

- (i) an exfoliation-promoting compound;
- (ii) an ultraviolet (UV) light protecting/sunscreen agent;
- 5 (iii) a retinoid;
- (iv) a skin lightening agent
- (v) an antioxidant;
- (vi) a skin cooling agent; and
- (vii) any mixtures thereof.

10

24. The topical composition of claim 22, wherein the at least one secondary component is selected from the group consisting of:

A topical composition comprising:

- (i) an exfoliation-promoting compound;
- 15 (ii) an ultraviolet (UV) light protecting/sunscreen agent;
- (iii) a retinoid; and
- (iv) any mixtures thereof.

25. The topical composition of claim 22, wherein the at least one secondary component is selected from the group consisting of:

- (i) an exfoliation-promoting compound;
- (ii) an ultraviolet (UV) light protecting/sunscreen agent;
- (iii) a skin lightening agent; and
- (vi) any mixtures thereof.

25

26. The topical composition of claim 22, wherein the at least one secondary component is selected from the group consisting of:

- (i) an ultraviolet (UV) light protecting/sunscreen agent;
- (ii) a retinoid;
- 30 (iii) a skin lightening agent; and
- (iv) any mixtures thereof.

27. The topical composition of claim 22, wherein the at least one secondary component is selected from the group consisting of:

- (i) an ultraviolet (UV) light protecting/sunscreen agent;
- (ii) a retinoid;
- 5 (iii) a collagen enhancing agent; and
- (iv) any mixtures thereof.

# INTERNATIONAL SEARCH REPORT

International application No

PCT/US99/20854

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 7/48  
US CL : 424/195.1, 401; 514/874

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/195.1, 401; 514/874

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
STN: USPATFULL, CAPLUS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P ---	US 5834513 A (PTCHELINTSEV et al.) 10 November 1998, col. 2, lines 60-col. 3, line 3; col. 4, lines 47-49; col. 5, lines 56-61; col. 6-col. 8; col. 9, lines 23-26.	14-27 -----
Y		1-13
X, P ---	US 5914116 A (SUARES et al.) 22 June 1999, col. 9, Table IV.	14-27 -----
Y		1-13
X, P Y	US 5935596 A (CROTTY et al.) 10 August 1999, col. 3-4. US 5569651 A (GARRISON et al.) 29 October 1996, abstract, example 3, col. 3-4, col. 7, lines 9-11.	14-27 1-27
Y	US 5605933 A (DUFFY et al.) 25 February 1997, col. 1, lines 40-53; col. 2, lines 39-52; col. 3, lines 52-54; col. 3, line 66-col. 4, line 1; col. 5, line 67-col. 6, line 10; col. 7, lines 38-62; col. 9, line 43.	1-27
Y	US 5643587 A (SCANCARELLA et al.) 01 July 1997, col. 1, lines 35-40; col. 2, lines 57-58; col. 2, line 65-col. 3, line 7; col. 3, lines 40-42; col. 4, line 33, example 2, Table 4.	1-27

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

Date of mailing of the international search report

24 FEB 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Thurman H. Page

Telephone No. 703/308-1234